Development and Evaluation of Safety and Effectiveness of Novel Cancer Screening Tests for Routine Clinical Use with Applications to Multicancer Detection Technologies

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2022 Feb 8

PMID 35133658

Authors

Chyke A Doubeni

Yan Kwan Lau

Jennifer S Lin

Gene A Pennello

Robert W Carlson

Affiliations

Soon will be listed here.

Abstract

Multicancer screening is a promising approach to improving the detection of preclinical disease, but current technologies have limited ability to identify precursor or early stage lesions, and approaches for developing the evidentiary chain are unclear. Frameworks to enable development and evaluation from discovery through evidence of clinical effectiveness are discussed.

Citing Articles

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications.

Parisi C, Tagliamento M, Belcaid L, Aldea M, Bayle A, Remon-Masip J J Liq Biopsy. 2025; 1:100007.

PMID: 40027283 PMC: 11863815. DOI: 10.1016/j.jlb.2023.100007.

FIT as a Comparator for Evaluating the Effectiveness of New Non-invasive CRC Screening Test.

Senore C, Doubeni C, Guittet L Dig Dis Sci. 2024; .

PMID: 39560807 DOI: 10.1007/s10620-024-08718-w.

The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.

Wisse P, de Klaver W, van Wifferen F, Meiqari L, Bierkens M, Greuter M BMC Cancer. 2022; 22(1):1299.

PMID: 36503495 PMC: 9743627. DOI: 10.1186/s12885-022-10372-2.

References

Moyer V . Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160(5):330-8. DOI: 10.7326/M13-2771. View

C Grossman D, Curry S, Owens D, Barry M, Davidson K, Doubeni C . Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 319(6):588-594. DOI: 10.1001/jama.2017.21926. View

Loeb S, Bjurlin M, Nicholson J, Tammela T, Penson D, Carter H . Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014; 65(6):1046-55. PMC: 4113338. DOI: 10.1016/j.eururo.2013.12.062. View

Reitsma J, Rutjes A, Khan K, Coomarasamy A, Bossuyt P . A review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard. J Clin Epidemiol. 2009; 62(8):797-806. DOI: 10.1016/j.jclinepi.2009.02.005. View

Ahn H, Kim H, Welch H . Korea's thyroid-cancer "epidemic"--screening and overdiagnosis. N Engl J Med. 2014; 371(19):1765-7. DOI: 10.1056/NEJMp1409841. View

Umemneku Chikere C, Wilson K, Graziadio S, Vale L, Allen A . Diagnostic test evaluation methodology: A systematic review of methods employed to evaluate diagnostic tests in the absence of gold standard - An update. PLoS One. 2019; 14(10):e0223832. PMC: 6788703. DOI: 10.1371/journal.pone.0223832. View

Usher-Smith J, Sharp S, Griffin S . The spectrum effect in tests for risk prediction, screening, and diagnosis. BMJ. 2016; 353:i3139. PMC: 4916916. DOI: 10.1136/bmj.i3139. View

Bast Jr R, Srivastava S . The National Cancer Institute Early Detection Research Network: Two Decades of Progress. Cancer Epidemiol Biomarkers Prev. 2020; 29(12):2396-2400. PMC: 7717495. DOI: 10.1158/1055-9965.EPI-20-1158. View

Feng Z, Pepe M . Adding Rigor to Biomarker Evaluations-EDRN Experience. Cancer Epidemiol Biomarkers Prev. 2020; 29(12):2575-2582. PMC: 8341386. DOI: 10.1158/1055-9965.EPI-20-0240. View

10.

Ren A, Fiala C, Diamandis E, Kulasingam V . Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA. Cancer Epidemiol Biomarkers Prev. 2020; 29(12):2568-2574. DOI: 10.1158/1055-9965.EPI-20-0074. View

11.

Bibbins-Domingo K, C Grossman D, Curry S, Barry M, Davidson K, Doubeni C . Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2017; 317(18):1882-1887. DOI: 10.1001/jama.2017.4011. View

12.

Marshall R . Validation study methods for estimating exposure proportions and odds ratios with misclassified data. J Clin Epidemiol. 1990; 43(9):941-7. DOI: 10.1016/0895-4356(90)90077-3. View

13.

Klein E, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D . Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021; 32(9):1167-1177. DOI: 10.1016/j.annonc.2021.05.806. View

14.

Prentice R . Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8(4):431-40. DOI: 10.1002/sim.4780080407. View

15.

Yu J, Blackford A, Dal Molin M, Wolfgang C, Goggins M . Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015; 64(11):1783-9. PMC: 4520782. DOI: 10.1136/gutjnl-2014-308653. View

16.

Cohen J, Li L, Wang Y, Thoburn C, Afsari B, Danilova L . Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018; 359(6378):926-930. PMC: 6080308. DOI: 10.1126/science.aar3247. View

17.

Reynolds E, Doubeni C, Sawhney M, Kanjee Z . Should This Patient Be Screened for Pancreatic Cancer? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med. 2020; 173(11):914-921. DOI: 10.7326/M20-6384. View

18.

Krist A, Davidson K, Mangione C, Barry M, Cabana M, Caughey A . Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021; 325(10):962-970. DOI: 10.1001/jama.2021.1117. View

19.

Lord S, Irwig L, Simes R . When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials?. Ann Intern Med. 2006; 144(11):850-5. DOI: 10.7326/0003-4819-144-11-200606060-00011. View

20.

Liu M, Oxnard G, Klein E, Swanton C, Seiden M . Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2021; 31(6):745-759. PMC: 8274402. DOI: 10.1016/j.annonc.2020.02.011. View